180 Wealth Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

180 Wealth Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Hold	8,321	–	–	0.03%	395
2026 Q1	$251K	Hold	8,321	–	–	0.03%	400
2025 Q4	$260K	Buy	+8,321	New	+$205K	0.03%	393
2021 Q4	–	Sell	-10,439	Closed	-$101K	–	407
2021 Q3	$101K	Hold	10,439	–	–	0.02%	373
2021 Q2	$105K	Buy	+10,439	New	+$110K	0.02%	356

Other funds holding TEVA

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

180 Wealth Advisors's TEVA Position: Q2 2026 in Review

180 Wealth Advisors held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 8,321 shares worth $282K. The position accounts for 0.03% of the portfolio, ranked #395.

180 Wealth Advisors first reported a position in TEVA in Q2 2021 and has held it in 5 quarters since. 99 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

180 Wealth Advisors held 8,321 shares of Teva Pharmaceuticals worth $282K as of Q2 2026.
180 Wealth Advisors left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.03% of 180 Wealth Advisors's portfolio in Q2 2026, its #395 holding.
180 Wealth Advisors first reported a position in Teva Pharmaceuticals in Q2 2021 and has held it in 5 quarters since.
99 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.